News | FFR Technologies | July 09, 2020

Acist Launches New Advance in FFR Microcatheters

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.


July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II Rapid Exchange fractional flow reserve (FFR) microcatheter, the second-generation microcatheter for use with its Acist RXi Rapid Exchange FFR System.

FFR measurements provide assessment of arterial lesion severity and inform intervention strategy in both diagnosis and treatment of coronary artery disease. This latest advance delivers the same level of control, consistency and accuracy that physicians have come to expect from the original Navvus microcatheter, with valuable new enhancements. Specifically, the Acist Navvus II features a streamlined crossing contour, 28 percent more flexibility[1] and a lesion entry profile reduced by 15 percent.[2] The result is a highly deliverable microcatheter that may improve procedural efficiency.

The Navvus II Rapid Exchange MicroCatheter and its predecessor, Navvus, are the only coronary physiology products that allow the use of the physician’s 0.014 inch guidewire of choice. This market distinction may enable more efficient, faster diagnostic and post-PCI physiological assessment because wire position is maintained throughout the procedure.

Recently, the FFR-SEARCH study reported an average of 5 minutes per lesion to assess physiology following the intervention using the Acist microcatheter-based system.[3] FFR-SEARCH is a robust and independent, physician-sponsored study that utilized a prospective, all-comers registry and over 600 patients were analyzed.

“This latest advance represents the company’s continued strategic commitment to our market-defining FFR technology,” said Kristen Knox, SVP, general manager, Acist Medical Systems. “Physicians know they can rely on Navvus—and now Navvus II—to easily and quickly guide treatment decisions by invasive physiologic measurement.”

For more information https://acist.com/products/acist-rxi/navvusii-catheter/

 
References:

1. TR-07888: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

2. TR-08707: Compared with Navvus FFR MicroCatheter in benchtop testing. Data on file at ACIST. May not be indicative of clinical performance.

3. Rutger J. van Bommel, Kaneshka Masdjedi, Roberto Diletti, et al. Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention. The FFR-SEARCH Study. Circulation: Cardiovascular Interventions. 2019;12. Originally published 25 Apr 2019. https://doi.org/10.1161/CIRCINTERVENTIONS.118.007428. 2019;12

 

Related Content

News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
News | Cath Lab

November 10, 2021 — Shockwave Medical a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...

Home November 10, 2021
Home
News | Cath Lab

November 10, 2021 — Philips Healthcare announced North American availability of new innovations in its portfolio of ...

Home November 10, 2021
Home
Subscribe Now